Market Signal Briefing

Clarus Corporation (CLAR) Q4 2025 Earnings Call March 5, 2026 5:00 PM EST

Company Participants

Warren Kanders - Executive Chairman
McNeil Fiske - President of Black Diamond Equipment
Michael J. Yates - CFO, Secretary & Treasurer

Conference Call Participants

Matthew Berkowitz - The IGB Group, Inc.
Matt Koranda - ROTH Capital Partners, LLC, Research Division
Anna Glaessgen - B. Riley Securities, Inc., Research Division
Lipeiwen Yang - BNP Paribas, Research Division
Alex Sturnieks - Lake Street Capital Markets, LLC, Research Division

Presentation

Operator

Good afternoon, everyone, and thank you for participating in today's conference call to discuss Clarus Corporation's financial results for the fourth quarter ended December 31, 2025. Joining us today are Clarus Corporation's Executive Chairman, Warren Kanders; CFO, Mike Yates; President of Black Diamond Equipment, Neil Fiske; and the company's External Director of Investor Relations, Matt Berkowitz. [Operator Instructions] Before we go further, I would like to turn the call over to Mr. Berkowitz as he reads the company's safe harbor statement within the meaning of Private Securities Litigation Reform Act of 1995 that provides important cautions regarding forward-looking statements. Matt, please go ahead.

Matthew Berkowitz
The IGB Group, Inc.

Thank you. Before we begin, I'd like to remind everyone that during today's call, we'll be making several forward-looking statements, and we will make these statements under the safe harbor provisions of the Private Securities Litigation Reform Act. These forward-looking statements reflect our best estimates and assumptions based on our understanding of information known to us today. These forward-looking statements are subject to potential risks and uncertainties that could cause the actual results of operations or financial conditions of Clarus Corporation to differ materially from those expressed or implied by the forward-looking statements. More information on potential factors that could affect the company's operating and financial results is included from time to time in the company's public reports filed

33.44K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Richtech Robotics Inc. (NASDAQ: RR) between January 27, 2026 and 12:00 PM ET on January 29, 2026, both dates inclusive (the "Class Period"), of the important April 3, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

So what: If you purchased Richtech Robotics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Richtech Robotics class action, go to https://rosenlegal.com/submit-form/?case_id=51742 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Richtech claimed that it had a collaborative and commercial relationship with Microsoft when it did not; and (2) as a result, defendants' statements about Richtech's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Richtech Robotics class action, go to https://rosenlegal.com/submit-form/?case_id=51742 https://rosenlegal.com/submit-form/?case_id=46039or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

HomeStock IdeasLong IdeasTech 

SummaryQnity Electronics is a newly spun-off semiconductor materials company, positioned to benefit from the AI/data center supercycle.Q's revenue is driven by consumables essential for advanced chip fabrication, with 2026 guidance of $4.97–$5.17B revenue and $3.55–$3.95 adjusted EPS.The company trades at a forward P/E of ~32x, below peers, and is leveraged to ongoing high-bandwidth memory demand and hyperscaler capex.Risks include cyclicality, management execution as a new standalone, valuation sensitivity, and potential geopolitical supply chain disruptions. Pavlo Sukharchuk/iStock via Getty Images

Executive Summary Qnity Electronics (Q) is a materials and solutions company for the semiconductor industry. The company was part of DuPont's electronic division and was spun off in November 2025. The company operates under two

73 Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of Q either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call March 5, 2026 4:30 PM EST

Company Participants

Ioana Hone - Director of Investor Relations
Brian Culley - CEO, President & Director
Jill Howe - CFO & Principal Financial and Accounting Officer

Conference Call Participants

Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division
Jack Allen - Robert W. Baird & Co. Incorporated, Research Division
Mayank Mamtani - B. Riley Securities, Inc., Research Division
Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division
Yang Chen - Raymond James & Associates, Inc., Research Division

Presentation

Operator

Welcome to the Lineage Cell Therapeutics Third (sic) [ Fourth ] Quarter 2025 Conference Call. [Operator Instructions] An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage. And recordings, reproductions or transmission of this call without the expressed written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded.

I would now like to introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead.

Ioana Hone
Director of Investor Relations

Thank you, Jamie. Good afternoon, and thank you for joining us. A press release reporting our fourth quarter and full year 2025 financial results was issued earlier today, March 5, 2026, and can be found on the Investors section of our website.

Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HF Sinclair Corporation ("HF Sinclair" or the "Company") (NYSE: DINO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether HF Sinclair and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 18, 2026, HF Sinclair announced that Chief Executive Officer and President Tim Go would "take a voluntary leave of absence from his duties" without disclosing a reason. 

 On this news, HF Sinclair's stock price fell $6.28 per share, or 10.86%, to close at $51.57 per share on February 18, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Northern Dynasty Minerals Ltd. ("Northern Dynasty" or the "Company") (NYSE: NAK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Northern Dynasty and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 17, 2026, the U.S. Department of Justice ("DOJ") filed a brief in U.S. District Court for the District of Alaska, supporting the Environmental Protection Agency's veto of the Company's proposed Pebble Mine in Southwest Alaska. 

On news of the DOJ brief, Northern Dynasty's stock price fell $0.80 per share, or 39.41%, to close at $1.23 per share on February 18, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

31.63K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRM, ORCL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Banco Santander, S.A. (NYSE: SAN) resulting from allegations that Santander may have issued materially misleading business information to the investing public.

So What: If you purchased Santander securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22671 https://rosenlegal.com/submit-form/?case_id=53703https://rosenlegal.com/submit-form/?case_id=47559 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On February 27, 2026, Reuters published an article entitled "Wall Street hit by UK mortgage lender collapse, raising fears of more credit 'cockroaches.'" The article stated that "Wall Street lenders on Friday were rocked by the implosion of little-known UK mortgage provider Market Financial Solutions Ltd, fueling concerns about wider losses among banks and reviving warnings of more "cockroaches" in the booming private credit industry." Further, it stated that Santander faces potential losses from the collapse.

On this news, Santander's American Depositary Shares ("ADSs") fell 4.48% on February 27, 2026, and a further 3.2% on February 28, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Enphase Energy, Inc. (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive (the "Class Period"), of the important April 20, 2026 lead plaintiff deadline.

So What: If you purchased Enphase securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Enphase class action, go to https://rosenlegal.com/submit-form/?case_id=25593 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Enphase overstated its ability to manage its channel inventory; (2) Enphase overstated its ability to mitigate effects arising from the termination of the Residential Clean Energy Credit; (3) accordingly, Enphase overstated its financial and operational prospects; and (4) as a result, Enphase's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Enphase class action, go to https://rosenlegal.com/submit-form/?case_id=25593 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

China's has set its lowest growth target in decades, acknowledging domestic challenges and pointing to global uncertainty, while keeping some stimulus measures in place to counter a possible ramp up in external shocks.

Beijing on Thursday announced its GDP growth target for 2026 at 4.5% to 5%, the least ambitious goal since early 1990s.

The lower target range leaves room for policymakers to "react to the external environment, which has seen increased uncertainty this year," Danyang Shen, head of the team that drafted the target-setting report, told reporters Thursday, according to a CNBC translation of the Chinese.

"Factors that are uncertain and difficult to predict may turn out to be more numerous than anticipated," he said, noting that "everyone has seen the latest global trend."

Barely three months into 2026, Beijing is facing heightened economic risks as the U.S.-Israel conflict with Iran, a critical oil supplier to China, risks Beijing's energy supply — that comes against the backdrop of the ouster of Nicolás Maduro in Venezuela, another major oil supplier to China.

China has reportedly ordered the largest state oil refiners to suspend exports of diesel and gasoline amid worries that the ongoing Iran conflict could disrupt easy access to energy. The U.S. military action in Middle East has also led to concerns over whether a meeting between U.S. President Donald Trump and his Chinese counterpart Xi Jinping later this month would take place as planned.

watch now

The lowered GDP target also recognizes the seriousness of persistent domestic growth headwinds.

Chinese Premier Li Qiang made a rare acknowledgement of the U.S. tariff impact during his presentation on the country's economic targets on Thursday. He also painted a stark picture of business struggles, along with persistent local government financial difficulties that have at times even led to delayed salary payments to employees.

The report was "surprisingly candid" that weak consumption and investment have weighed heavily on growth momentum," said Han Shen Lin, China country director at The Asia Group.

But it's "ultimately a matter of confidence about the future," Lin said. "Nothing in the plan really addresses this concern so the market's takeaway will be 'more deflation in the horizon.'" Chinese consumer prices remained flat last year, compared with "around 2%" growth target.

Although Beijing lowered its headline GDP target range, it kept other goals such as consumer inflation and fiscal spending largely in line with last year, when the targeted economic growth was around 5%.

"I think people already feel the economy is not growing [at] 5%," said Liqian Ren, director of Mordern Alpha at U.S.-based fund manager WisdomTree. Lowering the GDP target "probably puts it closer to what people feel on the ground."

"Ordinary people, they care about the unemployment situation the most," she said. China's youth unemployment rate remained elevated, standing at 16.3% in January, while the nation-wide jobless rate averaged 5.2% last year. For comparison, the youth jobless rate was at 9% in the U.S. in January.

The Chinese government on Thursday pledged to create 12 million urban jobs with an urban jobless rate at "around 5.5%." It did not share specific plans for doing so.

Tech, not real estateDespite a persistent downward spiral in the property market, Beijing plans aimed at arresting the decline in the sector were similar to those detailed last year — and Thursday's work report even labeled those efforts as "effective."

Meanwhile, policymakers continued to double down on achieving tech self-sufficiency. For the upcoming five years, Beijing said it would ramp up investment into scientific research and improve the environment to be more conducive to innovation.

So far, the push into high-tech industries has not been able to offset the growth drags. New industries such as AI, robotics and electric cars added just 0.8 percentage point to its GDP from 2023 to 2025, according to research firm Rhodium Group. Meanwhile, traditional sectors including real estate saw a combined 6 percentage point decline during the same period.

A minimum level for growthExports growth remains the "main swing factor," said Larry Hu, head of China economics at Macquarie. "If exports remain strong, policymakers may continue to tolerate weak domestic consumption. Conversely, if exports falter, they will step up domestic stimulus to defend the GDP target."

China plans to issue 1.3 trillion yuan ($188.5 billion) in ultra-long-term special treasury bonds in 2026, same as last year, and allocate 250 billion yuan to support consumer goods trade-in program — pared down from 300 billion yuan last year.

"This signals Beijing's explicit shift from crisis-response stimulus to preserving policy space for 2027-2030," said Jeremy Stevens, Beijing-based Asia economist at Standard Bank.

That said, the modest growth target will still put the world's second-largest economy on track to achieving its goal of doubling its size by 2035 from the 2020 levels, as per Beijing's longer-term goals. Shen estimated that China's economy just needs to grow an average 4.17% annually over the next decade to achieve the 2035 target.

China's leaders would "rather beat a modest number than miss a bold one," The Asia Group's Lin said.

Weekly analysis and insights from Asia's largest economy in your inbox
Subscribe now

One of the frustrating things about investing in companies is that even when they're making progress toward their goals, the results may not happen fast enough. Unfortunately, I think that's what's happening with Lucid (LCID 4.04%) and its goal of increasing vehicle production to between 25,000 to 27,000 vehicles this year.

While the company saw impressive production gains in 2025, the current year's guidance represents a slowdown in growth. And it comes as the electric vehicle (EV) industry is in a tough spot.

Image source: Lucid.

Lucid is making some progress with its vehicle production Lucid recently reported its 2025 production, which nearly doubled from the previous year to 17,840 vehicles. Management has been working for years to ramp up manufacturing, which has been complicated the COVID-19 pandemic, tariffs, and flurry of management changes over the past several years. Lucid is on its second CEO since going public in 2019.

Management is guiding for a significant increase in production this year, though not as strong as last year, with production expected to rise between 40% and 51% and reach up to 27,000 vehicles. Lucid's CFO, Taoufiq Boussaid, noted that the most recent quarter saw a "step-change in production and unit economics," and that the progress it made will help create a "repeatable and stable operating cadence heading into 2026."

Lucid is on a rough road, and it's unclear what's around the bend The company's production increase in 2025 and production guidance for this year may make it seem like it is on the right path. But I think investors should take a more critical look at what's happening with the company.

First, while Lucid expects to increase its vehicle production this year, it's far less than last year. Lucid nearly doubled production in 2025, but estimates it'll make just 51% more vehicles this year than last year. That's especially notable because Lucid made fewer than 18,000 vehicles last year. Not exactly an impressive amount and far below fellow EV start-up Rivian's production of 42,284 cars.

Today's Change

(

-4.04

%) $

-0.41

Current Price

$

9.86

What's more, the production guidance looks even more disappointing considering that Lucid will begin building a new mid-sized EV that later this year. The new model will start at just under $50,000 and could eventually play an important part in helping Lucid appeal to more budget-conscious buyers. Lucid's interim CEO Marc Winterhoff said on the fourth-quarter earnings call that there won't be any "meaningful" production of its midsize vehicle this year. I think this makes Lucid's production estimates even more lackluster, considering the company will have three models in production -- versus two now -- and yet production growth will slow from last year.

And finally, Lucid and other automakers are facing a difficult consumer environment. Not only have the EV tax credits expired (of which Lucid benefited through a leasing loophole), but consumer demand for EVs is generally slowing down. A 2025 AAA poll found that just 16% of American car buyers said they were "likely" or "very likely" to buy an EV, the lowest level since 2019.

Americans are also unenthusiastic about the economy, with a recent Pew Research survey showing that 72% of Americans say recent economic conditions are "fair" or "poor." Lucid can't single-handedly fix EV demand, and it can't do anything about Americans' pessimism about the economy, but they're serious problems for the luxury EV maker nonetheless, considering its cheapest vehicle starts at around $70,000 right now.

When you add all of the above together, I think it points to a difficult year ahead for Lucid. Current shareholders should expect volatility ahead, and potential investors should probably hold off on buying Lucid for now.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In China Liberal (CLEUF) To Contact Him Directly To Discuss Their Options

If you purchased or acquired CLEU Shares between January 22 and January 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against China Liberal Education Holdings Ltd. (“China Liberal” or the “Company”) (OTCMKTS: CLEUF) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired CLEU Shares between January 22 and January 30, 2025, both dates inclusive (the “Class Period”).Investors have until March 31, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:

According to the complaint, China Liberal utilized illegal means of obtaining value of the Company's public listing – coordinating with criminal scammers to carry out a pump-and-dump scheme involving the Company's shares. The complaint alleges that scammers recruited victims through advertisements on the Facebook and Instagram social media platforms promoting supposed investment clubs associated with celebrities, well-known investors, and advisory firms. Victims were led to WhatsApp groups, where scammers posed as financial advisors and encouraged victims to purchase securities whose prices the scammers were manipulating so that their co-conspirators could unload their holdings at artificially inflated prices, reaping massive illegal profits.Plaintiffs allege that the market became aware of this fraud on January 30, 2025, and that as a result, the stock price immediately collapsed, harming investors in excess of $300 million. Next Steps:

If you purchased or otherwise acquired China Liberal shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Thinkific Labs Inc. (THNC:CA) Q4 2025 Earnings Call March 5, 2026 5:00 PM EST

Company Participants

Joo-Hun Kim - Investor Relations Contact
Greg Smith - Co-Founder, CEO & Director
Corinne Hua - Chief Financial Officer

Conference Call Participants

Stephen Machielsen - BMO Capital Markets Equity Research
Gavin Fairweather - ATB Cormark Capital Markets Inc., Research Division
Robert Young - Canaccord Genuity Corp., Research Division
Thomas Ingham - CIBC Capital Markets, Research Division

Presentation

Operator

Good afternoon. My name is Ina, and I will be your conference operator today. I would like to welcome everyone to Thinkific's Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions]

I would now like to turn the conference call over to Joo-Hun Kim, Head of Investor Relations. Please go ahead.

Joo-Hun Kim
Investor Relations Contact

Thank you, and good afternoon, everyone. Welcome to Thinkific's Fourth Quarter and Full Year 2025 Financial Results Earnings Call. Joining me today are Greg Smith, CEO and Co-Founder of Thinkific; and Corinne Hua, CFO. After the prepared remarks, we will open up the call to questions.

During the call today, we will discuss our business outlook and make forward-looking statements that are based on assumptions and therefore, subject to risks and uncertainties that could cause actual results to differ materially from those projected. These comments are based on our predictions and expectations as of today. We undertake no obligation to update these statements, except as required by law. You can read about these risks and uncertainties in our regulatory filings that were filed earlier today.

Our commentary today will include adjusted financial measures, which are non-IFRS measures. They should be considered as a supplement to and not a substitute for IFRS measures. Reconciliations between the two can be found in our regulatory documents, which are available on our website.

In

Fidelity High Dividend ETF maintains a 'buy' rating due to its attractive fundamentals, despite the recent removal of all energy sector exposure. FDVV trades at 17.26x forward earnings, offers a 2.88% estimated yield, and features double-digit earnings growth with higher EBIT margins than the S&P 500. The ETF employs a 'barbell' strategy, balancing high-growth mega-caps with stable, high-yield stocks, reducing correlation and risk.

Gevo, Inc. (GEVO) Q4 2025 Earnings Call March 5, 2026 4:30 PM EST

Company Participants

Eric Frey - Vice President of Finance & Strategy
Patrick Gruber - CEO & Executive Chair
Paul Bloom - President & Director
Oluwagbemileke Agiri - Chief Financial Officer
Christopher Ryan - Chief Operating Officer

Conference Call Participants

Jeffrey Grampp - Northland Capital Markets, Research Division
Dushyant Ailani - Jefferies LLC, Research Division
Sameer Joshi - H.C. Wainwright & Co, LLC, Research Division
Derrick Whitfield - Texas Capital Securities, Research Division
Peter Gastreich - Water Tower Research LLC

Presentation

Operator

Thank you for standing by. Welcome to Gevo's Fourth Quarter 2025 Earnings Conference Call.

[Operator Instructions]

As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Eric Frey, Vice President of Finance and Strategy. Please go ahead, sir.

Eric Frey
Vice President of Finance & Strategy

Good afternoon, everyone, and thank you for joining us on today's call to discuss Gevo's Fourth Quarter and Full year 2025 results. I'm Eric Frey, Vice President of Finance and Strategy at Gevo. With me today, we have Patrick Gruber, our Chief Executive Officer; Paul Bloom, our President; Leke Agiri, our Chief Financial Officer; and Chris Ryan, our Chief Operating Officer.

Earlier today, we issued a press release that outlines our fourth quarter and full year 2025 results and some of the topics we plan to discuss as well as a slide presentation that we will discuss on today's call. Copies of the press release and the slide presentation are available on our website at www.gevo.com.

Please be advised that our remarks today, including answers to your questions, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are subject to risks and uncertainties that could cause actual results to be materially different from

March 05, 2026 20:30 ET  | Source: Quipt Home Medical Corp.

CINCINNATI, March 05, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announces that the Supreme Court of British Columbia issued a final order today in connection with the previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”) pursuant to which affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC will acquire all of the issued and outstanding common shares of the Company (each, a “Share”) for cash consideration of US$3.65 per Share. The final order was the final substantive court approval required prior to the closing of the Arrangement. Assuming all other terms and conditions to the Arrangement are satisfied, it is expected that the Arrangement will be completed by March 16, 2026.

It is anticipated that the Shares will be delisted from the Toronto Stock Exchange (“TSX”) and the Nasdaq Capital Markets (“NASDAQ”) and that the Company will cease to be a reporting issuer in all jurisdictions in which it is a reporting issuer under applicable securities laws, in each case shortly after completion of the Arrangement.

The terms of the Arrangement and the arrangement agreement among the Company, 1567208 B.C. Ltd. and REM Aggregator, LLC dated December 14, 2025 are further described in the Company’s management information circular and proxy statement dated January 23, 2026 and related materials for the special meeting of shareholders of the Company held on March 3, 2026, all of which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

ABOUT QUIPT HOME MEDICAL CORP.‎

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to offer a broader range of services to patients in need of in-home monitoring and chronic disease management.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “postulate”, “expect”, “outlook”, or the negatives thereof or variations of such words, and similar expressions as they relate to the Company are intended to identify forward-looking statements, including: the proposed Arrangement and terms thereof; and other statements that are not historical fact. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the ability to obtain the necessary regulatory and other third party approvals for the Arrangement, the timing of obtaining such approvals and the risk that such approvals may not be obtained in a timely manner or at all, and the risk that such approvals may be obtained on conditions that are not anticipated; the anticipated completion of the Arrangement and timing thereof; the abilities of the parties to satisfy, in a timely manner, the other conditions to the closing of the Arrangement; the delisting of the Shares from the TSX and NASDAQ; the Company ceasing to be a reporting issuer under Canadian and U.S. federal securities laws and the timing thereof; the failure of the Arrangement to close for any other reason; and the ability to achieve the expected benefits of the Arrangement. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; legal proceedings and litigation, including as it relates to the civil investigative demand received from the Department of Justice; increased competition; changes in foreign currency rates; the imposition of trade restrictions such as tariffs and retaliatory counter measures; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company and a smaller reporting company; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the SEC and available on EDGAR at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statement prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

For further information please visit our website at www.quipthomemedical.com, or contact:‎

Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
‎859-300-6455
[email protected]

Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
‎859-300-6455
[email protected]

Brad Chastain, global head of research for the U.S. Money Reserve, says institutional investors are once again pilling into gold. The reason?

Martinrea International Inc. (MRE:CA) Q4 2025 Earnings Call March 5, 2026 5:00 PM EST

Company Participants

Robert Wildeboer - Executive Chairman of the Board
Pat D'Eramo - CEO & Director
Fred Di Tosto - President
Peter Cirulis - CFO & Lead of Lightweight Structures Commercial Group

Conference Call Participants

Ty Collin - CIBC Capital Markets, Research Division
Michael Glen - Raymond James Ltd., Research Division
Brian Morrison - TD Cowen, Research Division

Presentation

Operator

Good evening, ladies and gentlemen. Welcome to the Fourth Quarter 2025 Results Conference Call. I would now like to turn the meeting over to Mr. Rob Wildeboer. Please go ahead.

Robert Wildeboer
Executive Chairman of the Board

Good evening, everyone. Thank you for joining today. We always look forward to talking to our shareholders, updating you on our business and answering your questions. We also note that we have other stakeholders, including many of our employees on the call, and our remarks will be addressed to them as well as we disseminate our results and commentary to our network. With me this evening are Pat D'Eramo, Martinrea's CEO; our President, Fred Di Tosto; and our CFO, Peter Cirulis.

Today, we will be discussing Martinrea's results for the fourth quarter and full year ended December 31, 2025. I refer you to our usual disclaimer in our press release and our filed documents. On this call, Pat will outline some key highlights and achievements in 2025, touch briefly on the quarter and comment on some of our key initiatives, including machine learning and artificial intelligence. Fred will discuss operations. Peter will go over the financials and our outlook for 2026 and beyond. And I will conclude with some comments on the current trade environment, capital allocation and valuation. Then, we'll open it up to Q&A. So without further ado, here's Pat.

AI chip leader Broadcom (AVGO - Free Report)  is emerging as a standout in a volatile trading week marked by Middle East tensions, rising oil prices, and private credit worries weighing on financial stocks.

Exceeding expectations for its fiscal first quarter on Wednesday evening, Broadcom stock spiked over 4% in today’s trading session, while the broader indexes declined, led by the Dow Jones' -1.61% drop.

Image Source: Zacks Investment Research

AI Chip Demand Drives Broadcom’s Record Q1 SalesHighlighting the accelerating adoption of its custom AI chips and AI networking components, Broadcom’s Q1 sales surged 29% year over year to a record $19.31 billion and edged estimates of $19.28 billion. The robust growth was driven by AI semiconductor revenue, which grew 106% YoY to $8.4 billion. On the bottom line, Q1 EPS spiked 28% to $2.05, topping expectations of $2.03.

Image Source: Zacks Investment Research

VMware’s Notable Contribution Best known for technologies that allow multiple operating systems and applications to run on a single physical server, Broadcom’s acquisition of VMware has continued to pay off. Specializing in virtualization and cloud computing, VMware was acquired by Broadcom in 2023.

What caught Wall Street’s attention is that with markets on edge about how AI could potentially disrupt software companies, Broadcom's comments centered on how AI is actually driving VMware’s growth and that the acquisition is fitting into its long-term strategy. Notably, Broadcom highlighted that VMware saw 13% growth during Q1, with $9.2 billion in total contract value.

Broadcom emphasized that VMware’s platform is essential for enterprises adopting private and hybrid cloud environments, describing the combined company as well-positioned to help customers build more secure and resilient infrastructure.

Favorable Guidance & Stock BuybacksWhile Broadcom’s top and bottom line beats weren’t eye-catching, the company’s guidance was well-received, with management expecting AI chip sales to double in Q2 as well, reinforcing confidence in sustained growth.

Broadcom expects AI semiconductor revenue for Q2 to increase 140% YoY to $10.7 billion. Overall, Broadcom guided Q2 sales at $22 billion, which would reflect 47% growth and came in well above Wall Street’s expectations of $20.44 billion (Current Qtr below).

Further fueling investor sentiment, Broadcom announced its board of directors has authorized an additional $10 billion share repurchase program effective through the end of calendar year.

Image Source: Zacks Investment Research

Bottom LineBroadcom’s latest results and commentary created a setup where the stock looks more attractive after Q1 because the company delivered strong performance, clear AI-driven growth visibility, and supportive capital-return actions. Broadcom stock currently lands a Zacks Rank #3 (Hold), but a buy rating could be on the way as a meaningful uptick in FY26 EPS revisions looks likely after its strong Q1 report and positive guidance. 

CarParts.com, Inc. (PRTS) Q4 2025 Earnings Call March 5, 2026 5:00 PM EST

Company Participants

Mark DiSiena - Interim CFO, Principal Financial Officer & Principal Accounting Officer
David Meniane - CEO & Director

Presentation

Operator

Good afternoon. [Operator Instructions] Please note, this call is being recorded.

I would now like to pass the conference over to our host, Mark DiSiena, Interim Chief Financial Officer. Please go ahead.

Mark DiSiena
Interim CFO, Principal Financial Officer & Principal Accounting Officer

Hello, everyone, and thank you for joining us for the CarParts.com Fourth Quarter of 2025 Conference Call. Joining me today is David Meniane, Chief Executive Officer.

Before I turn it over to David to start the call, I have some important disclosures. Our remarks on this call could contain certain forward-looking statements related to our company and our strategic initiatives under the federal securities laws. Actual results may differ materially from those contained herein or implied by these forward-looking statements due to various risks and uncertainties. For a discussion of material risks and other important factors that could affect results, please refer to CarParts.com annual report on Form 10-K and quarterly reports on Form 10-Q, each as filed with the SEC, all of which can be found on our Investor Relations website.

On the call, both GAAP and non-GAAP financial measures will be discussed. A reconciliation of GAAP to non-GAAP financial measures is provided in the press release that we issued today.

With that, I would now like to turn the call over to David.

David Meniane
CEO & Director

In 2025, we closed the $35.7 million strategic investment, completed a full cost structure reset and built an operating model that is now delivering results every quarter. Our A-Premium partnership is already at a $35 million annual revenue run rate with a clear path to $50 million in

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Barclays plc (NYSE: BCS) resulting from allegations that Barclays may have issued materially misleading business information to the investing public.

So What: If you purchased Barclays securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=23523 https://rosenlegal.com/submit-form/?case_id=53703https://rosenlegal.com/submit-form/?case_id=47559or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On February 27, 2026, Reuters published an article entitled "Wall Street hit by UK mortgage lender collapse, raising fears of more credit 'cockroaches.'" The article stated that lenders were "rocked by the implosion of little-known UK mortgage provider Market Financial Solutions Ltd ["MFS"], fuelling concerns about wider losses among banks and reviving warnings of more "cockroaches" in the booming private credit industry." It further stated that another publication "reported Barclays has a 600 million pound ($809.70 million) exposure to MFS."

On this news, Barclays American Depositary Shares ("ADS") fell 3.99% on February 27, 2026, and 2.3% on March 2, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

New York, NY, March 05, 2026 (GLOBE NEWSWIRE) -- Where this report uses terms such as "evaluating" or "examining," it refers to a neutral assessment of publicly available marketing statements and policies as published by the company — not an opinion, endorsement, or performance judgment. All details should be verified on the official website. This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or cosmetic advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

In this report, terms such as "results," "growth," or "effectiveness" refer strictly to how HaloGrow Hair Spray marketing materials describe potential outcomes. These terms do not indicate that HaloGrow Hair Spray has been clinically proven effective as a finished proprietary formula.

Individual results vary. Topical hair care products are not substitutes for professional dermatological evaluation, balanced nutrition, or medical treatment for underlying hair loss conditions. Consult a qualified healthcare provider before starting any new hair care regimen, particularly if you are currently managing an existing scalp condition or taking prescription medications.

What Consumer Searches About HaloGrow Hair Spray Look Like in 2026

Search interest surrounding HaloGrow Hair Spray has increased in early 2026 as consumers research topical solutions marketed for thinning hair. Queries such as "HaloGrow legitimate," "HaloGrow complaints," "HaloGrow ingredients," and "Halo Grow Hair Spray side effects" reflect consumers attempting to verify product claims beyond promotional summaries.

This report examines publicly available company materials and ingredient research context to help readers understand how the product is positioned and what verification steps consumers often review before purchasing.

Consumer concern patterns in the topical hair growth category tend to cluster around five categories: ingredient transparency, evidence type, refund and fulfillment requirements, marketing claim context, and brand accountability. HaloGrow Hair Spray generates search queries across all five of those categories. Rather than addressing them with generic reassurances, this evaluation examines each concern against what the company's own published materials actually state — and what they leave unaddressed.

Here is what consumers can verify independently versus what the company's marketing materials state: the official website describes HaloGrow Hair Spray as containing a blend of biotin, caffeine, castor oil, aminexil, ginger root extract, and He Shou Wu. The company's marketing materials reference a "56% thicker and longer hair in just 18 weeks" claim, presented alongside an asterisk disclaimer. What consumers can verify at this stage is whether any published study has tested the finished HaloGrow Hair Spray formula as sold. Publicly available sources reviewed for this report do not indicate one. That distinction shapes every concern addressed below.

Evidence standard used in this report: (1) company-published pages including the product page, refund policy, and terms of service; (2) ingredient-level peer-reviewed research where relevant to disclosed ingredients; and (3) consumer verification steps that can be completed prior to purchase. Ingredient studies referenced below do not establish clinical proof of the finished HaloGrow Hair Spray formula.

Readers can view the current HaloGrow Hair Spray details on the official product page.

HaloGrow Hair Spray Ingredient Research Context

If you are considering HaloGrow Hair Spray, the ingredient list is where your research should start — and where the most important questions live. The official website lists six primary active ingredients. Several of these compounds have appeared in published research related to scalp health or hair follicle biology. But published research on an ingredient and published research on this specific product are two very different things, and understanding that distinction can help readers interpret marketing statements in context.

Here is what is publicly disclosed about each ingredient and what the available research actually says.

Biotin (Vitamin B7)

Biotin is one of the most widely recognized ingredients in the hair care space, and there is a reason for that. It plays a well-documented role in keratin production — keratin being the structural protein that makes up your hair strands, your nails, and parts of your skin. A biotin deficiency can absolutely contribute to hair thinning and brittleness, and supplementing biotin in deficiency states has been associated with improved hair outcomes in published nutritional research.

The question with HaloGrow is more specific: what does the evidence say about topical biotin application on the scalp? This is where the picture becomes more nuanced. Most of the published clinical evidence for biotin and hair growth involves oral supplementation, not topical delivery. The rationale for topical application is that it delivers the compound directly to the follicle — which makes intuitive sense. But the peer-reviewed clinical data supporting topical biotin specifically for hair growth in individuals without a biotin deficiency is more limited than the evidence for oral forms. That doesn't mean topical biotin is ineffective; it means the evidence base isn't as deep as the marketing might suggest.

Caffeine

You probably didn't expect your morning coffee ingredient to show up in a hair spray, but caffeine has become one of the more interesting compounds in trichology research (trichology being the science of hair and scalp health). Published in-vitro studies — meaning laboratory studies conducted on hair follicle cells outside the human body — have examined caffeine's effects on hair follicle growth parameters. Some findings suggest that caffeine may counteract certain suppressive effects of DHT (dihydrotestosterone) on follicular keratinocytes, and that it may extend the growth phase of the hair cycle.

A study published in the International Journal of Dermatology examined topical caffeine solutions in relation to hair growth markers, and there is a growing body of research exploring caffeine as a topical active in hair care formulations. Research has examined this ingredient at the laboratory or cellular level under defined conditions. The key limitation is that HaloGrow's marketing references caffeine's DHT-related properties broadly, but the specific concentration of caffeine per spray application in HaloGrow is not publicly disclosed. Published studies used defined concentrations under controlled conditions — and without knowing the concentration in this product, consumers can't determine whether the research findings translate to this specific formulation.

Aminexil

Aminexil is a compound that appears in multiple cosmetic hair formulations and has been examined in research related to perifollicular fibrosis. Aminexil is structurally related to minoxidil, an FDA-approved topical medication for certain types of pattern hair loss, and it has been examined in research related to perifollicular fibrosis — the hardening of collagen around the hair root that can contribute to premature shedding and follicle miniaturization.

Perifollicular fibrosis refers to stiffening of the collagen sheath around the follicle, which some researchers describe as potentially influencing follicle function and shedding patterns over time. Aminexil's studied mechanism involves keeping that collagen supple, which may help hair remain more firmly anchored in the scalp. This proposed mechanism has been discussed in published research, including work associated with aminexil's development history.

The consideration for consumers: published aminexil studies typically specify the concentration and application protocol used. HaloGrow lists aminexil as an ingredient but doesn't appear to disclose the specific concentration per application. This makes it difficult to compare the product's aminexil content to the amounts used in published research.

He Shou Wu (Radix Polygoni Multiflori)

He Shou Wu, also known as Fo-Ti, has a long history in traditional Chinese medicine for hair and longevity-related applications. The name literally translates to "Mr. He's black hair," which gives you an idea of its traditional reputation. In Chinese herbal medicine, it has been used for centuries as a tonic for hair health, and there is published research examining some of its bioactive compounds — including stilbene glycosides and anthraquinones — in relation to hair follicle stimulation and melanin production.

However, clinical evidence in peer-reviewed Western dermatology journals specifically evaluating He Shou Wu for hair growth remains limited. Some published research exists in Traditional Chinese Medicine journals and in preliminary cell-culture studies, but large-scale randomized controlled trials are not prominent in the literature. This ingredient sits in a category where traditional use history is long and compelling, but modern clinical evidence is still developing.

Ginger Root Extract

Ginger has well-documented anti-inflammatory and circulation-stimulating properties in published research. The rationale for including ginger in a hair growth formulation relates to scalp health: improved blood flow to the scalp can enhance nutrient delivery to hair follicles, and reducing inflammation can create a healthier environment for hair growth. Ginger root extract also has antimicrobial properties that may help maintain a cleaner scalp by reducing excess oils and microbial buildup.

Published research on ginger and hair growth is mixed. Some in-vitro studies have examined specific ginger compounds (particularly 6-gingerol) in relation to hair follicle cells, with varying results depending on the study design and concentration used. As a scalp health ingredient, ginger has reasonable supporting evidence for its circulation and anti-inflammatory effects. As a direct hair growth stimulant, the evidence is less definitive.

Cold-Pressed Castor Oil

Castor oil is a traditional hair care ingredient with a long history of anecdotal use across multiple cultures. It is rich in ricinoleic acid, a fatty acid with anti-inflammatory and moisturizing properties. Castor oil can help hydrate the scalp, reduce flaking, and coat hair strands to reduce breakage and improve texture.

What castor oil does well, based on available evidence, is condition and protect existing hair. The evidence for castor oil as a direct growth stimulant is more limited. A 2003 study found that ricinoleic acid has prostaglandin-modulating properties that could theoretically support follicle activity, but this has not been validated in large-scale clinical trials for hair growth specifically. Castor oil's role in a formulation like this is more likely as a conditioning and scalp-health ingredient than as a primary growth driver.

Additional Ingredients (Per Public Product Listings)

A public product listing provides a fuller ingredient panel that additionally identifies Deionised Water and Ethanol as the base, along with Hydrolysed Oat Protein (a conditioning agent that can improve hair texture and reduce breakage), Angelica Archangelica Root Extract (a botanical traditionally used for scalp health), Ginseng Root Extract (which has published research related to circulation and cellular energy), Panthenol (provitamin B5, a well-established hair conditioning ingredient), Polysorbate 20 (an emulsifier), and Zinc PCA (which helps regulate sebum production on the scalp).

These additional ingredients are consistent with a topical hair care formulation focused on scalp health and hair conditioning. Several of them — particularly panthenol and zinc PCA — have well-established roles in cosmetic hair care, though they are generally considered conditioning or scalp-balancing ingredients rather than primary growth stimulants.

Ingredient Transparency Considerations

One factor consumers often evaluate when researching topical hair products is ingredient transparency. While the ingredients listed in HaloGrow Hair Spray appear in various cosmetic and trichology formulations, publicly available materials reviewed for this report do not appear to disclose specific per-ingredient concentrations per application. Without concentration disclosure, consumers can't easily compare the product's per-application delivery to concentrations used in published ingredient-level research.

Does HaloGrow Hair Spray Have Product-Level Clinical Evidence?

This question matters more than any individual ingredient deep-dive, because it addresses the core distinction that separates marketing from evidence.

A review of publicly available materials on the official website — including the product page, marketing content, and available policies — did not identify a published clinical trial evaluating HaloGrow Hair Spray as a finished proprietary formula. The ingredient descriptions and marketing references on the product website correspond to studies on individual ingredients tested in isolation under specific research conditions. Those studies examined single compounds at known concentrations — they did not evaluate the combined multi-ingredient topical spray as sold.

The brand's marketing states that ingredients like biotin, caffeine, castor oil, and aminexil are "clinically proven to target thinning hair, and stimulate the growth of new hair follicles." An asterisk appears alongside this language. This type of phrasing is common across the hair care and supplement industries. It describes ingredient-level research findings — not clinical validation of HaloGrow as a finished formulation.

Under current federal regulations, cosmetic products and topical hair care sprays are not required to undergo pre-market clinical testing or receive FDA approval before being sold. The FDA does not evaluate cosmetic product efficacy claims prior to market entry. The company's website includes a disclaimer stating that results may vary and that the product does not constitute medical advice.

Consumers researching terms such as "HaloGrow clinical study," "Halo Grow FDA approved," "HaloGrow Hair Spray proven," or "does HaloGrow actually work" should understand that the distinction between ingredient-level research and product-level clinical validation is the most important factor in interpreting the company's marketing references. That's standard across the industry, but it's especially important to understand when you're making a purchasing decision based on growth-related marketing claims.

Hair Growth Cycle Basics: Why Timelines and "Results" Claims Vary

Hair growth occurs in three primary phases: anagen (active growth), catagen (transition), and telogen (resting and shedding). Because follicles rotate through these phases on different timelines, changes in shedding, thickness, or density can vary widely between individuals and often take weeks or months to become noticeable.

In androgenetic alopecia (pattern hair loss), hair follicles can undergo a process called miniaturization, where each successive growth cycle produces thinner, shorter hair. Over time, the anagen phase may shorten and the telogen phase may lengthen, contributing to gradual thinning in characteristic patterns.

This biological context is one reason consumers evaluating topical hair products often look for clarity on three points: (1) whether the product has finished-formula clinical evidence, (2) whether the active ingredients are present at research-relevant concentrations, and (3) what timeframe the company's marketing claims reference. Individual timelines also vary based on factors such as genetics, age, scalp health, underlying medical conditions, nutritional status, stress levels, and consistency of use.

The DHT Hair Loss Mechanism: What HaloGrow Claims and What Research Supports

If you have been researching hair loss solutions, you have almost certainly encountered the term DHT. It is one of the most important concepts in understanding why hair thins — and it is central to HaloGrow's marketing narrative. Understanding what DHT actually does, and how different products approach it, will help you evaluate HaloGrow's claims in context.

What DHT Is and Why It Matters

DHT stands for dihydrotestosterone, an androgen hormone derived from testosterone through the action of an enzyme called 5-alpha reductase. DHT isn't inherently harmful — it plays roles in normal development and physiological function. But in people genetically predisposed to androgenetic alopecia (the most common form of pattern hair loss in both men and women), DHT can bind to receptors in scalp hair follicles and trigger a process called follicular miniaturization.

Miniaturization is what makes hair progressively thinner and shorter over successive growth cycles. The follicle doesn't die immediately — it slowly shrinks, producing weaker and finer hair until eventually the visible hair becomes barely perceptible or stops growing altogether. This process can take years, which is why pattern hair loss is gradual rather than sudden for most people.

How HaloGrow Positions Its DHT Approach

HaloGrow's marketing describes the product as delivering "DHT-blocking ingredients" directly to the scalp. The primary ingredient associated with this claim is caffeine. As discussed in the ingredient section above, published in-vitro research has examined caffeine's effects on hair follicle cells in relation to DHT, with some findings suggesting that caffeine may counteract certain suppressive effects of DHT on follicular keratinocytes.

The marketing also references the product's topical delivery mechanism as an advantage — stating that spraying ingredients directly onto the scalp bypasses the digestive system and delivers active compounds where they are needed. This is a commonly cited rationale for topical versus oral delivery, though the practical effectiveness depends entirely on the specific formulation, the concentrations of active compounds, and how well those compounds penetrate the scalp to reach the follicle.

FDA-Approved Treatments for Pattern Hair Loss

For perspective, the two FDA-approved treatments for pattern hair loss operate through well-established mechanisms with extensive clinical trial data:

Minoxidil (the active ingredient in Rogaine) is a topical treatment that operates primarily by increasing blood flow to hair follicles and potentially extending the growth phase of the hair cycle. It has been evaluated in multiple randomized controlled trials and is available over the counter.

Finasteride (the active ingredient in Propecia) is an oral prescription medication that operates by inhibiting 5-alpha reductase, the enzyme that converts testosterone to DHT. By reducing systemic DHT levels, it slows follicular miniaturization. It has extensive clinical trial data supporting its use for pattern hair loss in men.

HaloGrow isn't positioned as equivalent to either of these treatments, and the product's marketing doesn't make that claim. The key distinction is that minoxidil and finasteride have been evaluated as finished products through the FDA approval process, including randomized controlled trials with defined endpoints. HaloGrow's DHT-related claims are based on ingredient-level research mechanisms, not on published clinical data demonstrating that this specific spray inhibits DHT activity at the follicular level in real-world application.

This distinction does not establish whether an individual will or will not experience changes with use. It clarifies the difference between ingredient-level research and finished-product clinical evidence. Consumers should evaluate DHT-blocking marketing claims with the understanding that ingredient-level research interest and product-level clinical proof operate on different evidence standards. Consumers with medically diagnosed pattern hair loss should consult a dermatologist to discuss the full range of treatment options, including FDA-approved therapies.

The "56% Thicker Hair" Marketing Claim: What Consumers Should Understand

The official website references a marketing statement indicating "56% thicker and longer hair in just 18 weeks," presented with an accompanying disclaimer. This is a high-visibility claim that naturally attracts consumer attention — and consumer questions.

Several questions arise from this positioning that consumers may want to investigate:

What is the source of the 56% figure? The official website presents this percentage as a marketing headline alongside an asterisk. Publicly available materials reviewed for this report did not identify a peer-reviewed clinical study evaluating the finished HaloGrow Hair Spray formulation corresponding to this percentage. Consumers may want to determine whether the figure is drawn from a published study on the finished product, a company-sponsored internal assessment, an ingredient-level study extrapolated to the formulation, or another source, and whether supporting documentation is publicly available.

What does "approved by certified doctor and published author" mean? The website references Lisa Danielson as a "certified doctor and published author." The specific credentials, specialization, and nature of the association — whether it constitutes a clinical endorsement, a formulation review, a scientific advisory role, or a marketing partnership — are not detailed on the product page reviewed for this report. Consumers may want to verify the nature and scope of this endorsement independently. Endorsements from medical professionals carry significant persuasive weight in consumer decision-making, which is why understanding the specifics matters.

How should consumers interpret asterisk-disclaimed marketing claims? When a marketing headline is followed by an asterisk, the asterisk typically corresponds to a disclaimer elsewhere on the page that qualifies the claim. In the case of health and cosmetic products, these disclaimers often indicate that results may vary, that the statement has not been evaluated by the FDA, or that the claim is based on limited data. Consumers should locate and read the full text associated with any asterisk before interpreting the headline at face value.

This evaluation doesn't conclude whether HaloGrow has or lacks utility as a topical hair care product. It focuses on clarifying how the performance-related marketing language should be interpreted when you're doing your own research.

HaloGrow Hair Spray Pricing and Availability Context

According to the official website, HaloGrow Hair Spray is currently offered in several package formats with different per-bottle pricing structures. At the time this report was prepared, publicly available product listings indicated the following:

1 Bottle (1 Month Supply): According to the official website, listed at approximately $29.99 per bottle, described as a promotional discount from a stated original price of $49.99, with free shipping included.

Buy 2 Get 2 Free (4 Months Supply): According to the official website, listed at approximately $19.99 per bottle, with free shipping included.

Buy 3 Get 3 Free (6 Months Supply): According to the official website, listed at approximately $19.99 per bottle, with free shipping included.

Pricing and availability may change at any time. Consumers should confirm current terms on the official product page before completing any purchase. The website describes the product as available exclusively through the official website, and the company advises against purchasing from third-party marketplace listings.

Readers can view the current HaloGrow Hair Spray pricing and availability on the official product page.

A Note on the Checkout Process

Consumers researching online-only cosmetic products frequently review independent consumer feedback platforms before purchasing. These platforms sometimes include discussions related to shipping timelines, checkout clarity, and refund processes reported by past buyers. Some consumer discussions related to HaloGrow reference questions about order quantities and final checkout totals.

As with any online-only purchase, consumers should review checkout screens carefully, confirm the exact quantity and total charge before completing payment, and save all order confirmation details including confirmation emails and transaction records. This is standard consumer protection practice for direct-to-consumer products sold exclusively through brand websites.

HaloGrow Refund Policy Overview

Understanding a company's refund policy before purchasing is one of the most practical consumer protection steps available, and it is especially important for products sold exclusively online.

According to the official website, HaloGrow offers a 30-day satisfaction guarantee from the date of receipt. The published policy states that if you are not satisfied within the first 30 days, you can request a refund by contacting the company through the HaloGrow Support Portal or by sending an email to the address provided inside the product packaging. According to the company, refunds are processed within 48 hours of the returned product being received, and the policy is described as "no questions asked."

The refund process includes specific requirements worth understanding before purchasing:

According to the official website, the product must be returned before the refund is processed. The buyer may be responsible for return shipping costs. The specific return address and procedures are provided by the company's support team upon initiating a refund request.

Note: Some publicly available consumer review sites include discussions from buyers who report varying experiences with the refund process, including questions about response times and return procedures. Consumer experiences with refund processes can vary, and it is standard practice to document all purchase details, save confirmation emails, and understand return requirements before ordering rather than after.

Consumers who prioritize return flexibility may want to confirm the exact refund terms, required return steps, and support contact methods on the official website before completing a purchase. Verify whether the guarantee applies to all package sizes and whether there are any conditions or time limits beyond the stated 30-day window.

HaloGrow Testimonials and Consumer Feedback Context

The official website includes customer testimonials describing individual experiences with the product. These testimonials describe outcomes such as new hair growth around the temples and crown, reduced shedding, improved hair thickness, and enhanced shine and texture. Some testimonials include attributed names and locations, and some are labeled as verified buyers.

Here is what consumers should understand about testimonials in the hair care category:

Testimonials describe individual experiences and don't establish typical outcomes. People who share positive feedback about products they purchased are self-selected — satisfied customers are more likely to post feedback than those with neutral or negative experiences. This is known as selection bias, and it applies across all consumer products, not just HaloGrow.

The company's published disclaimer states that results may vary from person to person and that the product is not intended to diagnose, treat, cure, or prevent any disease. This is standard regulatory language for cosmetic and supplement products.

Additionally, the marketing materials reference a product rating and review count. Review counts and ratings that appear on a company's own website are typically curated by the company and may not represent the full spectrum of consumer experiences. Independent review platforms provide a broader picture of consumer sentiment, including both positive and negative experiences.

When evaluating testimonials, look for specific details about duration of use, consistency of application, and whether the user made other changes to their hair care routine simultaneously. One-product attributions for complex outcomes like hair growth — which is influenced by genetics, diet, stress, hormonal balance, and multiple other factors — should be interpreted with appropriate context.

Topical Spray Format: What the Delivery Method Means

HaloGrow is marketed as a topical spray rather than an oral supplement, a cream, or a serum. The company positions this delivery format as an advantage, stating that topical application delivers active ingredients directly to the scalp, "bypassing the digestive system for maximum potency."

Topical delivery is commonly used in hair care and dermatology because it applies ingredients directly to the scalp surface. When you apply a compound directly to the scalp, the active ingredients have the potential to reach the follicle without being metabolized by the digestive system first. This is why minoxidil — the FDA-approved topical hair loss treatment — is applied directly to the scalp rather than taken as a pill (though oral minoxidil exists as a separate treatment option).

However, topical delivery effectiveness depends on several factors that are specific to each formulation:

Penetration: Not all compounds applied to the scalp surface actually penetrate deep enough to reach the hair follicle. The scalp has a natural barrier function, and formulation chemistry — including the base, penetration enhancers, and molecular size of active ingredients — determines how effectively compounds are absorbed.

Concentration: Even if a compound penetrates the scalp, the concentration must be sufficient to produce a biological effect at the follicular level. This is why concentration disclosure matters for consumer evaluation.

Contact time: How long the product remains on the scalp before being washed out or evaporating affects absorption. HaloGrow's instructions offer the option of rinsing after 30 minutes or leaving it in, which suggests the company considers both approaches viable.

The spray format itself is a practical choice for daily use — it is lightweight, non-greasy according to the company, and easy to apply. Whether the specific formulation delivers its active ingredients effectively at the follicular level is a question that would require product-level testing data to answer definitively.

Who Might Consider HaloGrow Hair Spray — and Who Might Not

Rather than making a recommendation for or against this product, here is a framework for thinking about whether it aligns with your specific situation and priorities.

HaloGrow Hair Spray may align well with people who:

Prefer topical over oral hair care approaches: If you want to apply hair care ingredients directly to your scalp rather than taking oral supplements, the spray format delivers compounds to the area where they are intended to work. This delivery approach has logical appeal, though effectiveness depends on the specific formulation.

Are exploring plant-based and naturally derived ingredients: The formula uses botanical ingredients including ginger root, castor oil, He Shou Wu, and ginseng root extract alongside B-vitamins and aminexil. If you prefer formulations that emphasize plant-derived compounds over pharmaceutical active ingredients, this product aligns with that preference.

Want a daily-use spray format that integrates easily into existing routines: The lightweight, non-greasy format (according to the company's description) is designed to work within your existing hair care routine — either rinsed out after 30 minutes or left in and styled over. If convenience and ease of use are priorities, this format may be appealing.

Are comfortable with ingredient-level rather than product-level evidence: If you understand and accept that the research references apply to individual ingredients studied in isolation rather than the finished product, and you are comfortable making a purchasing decision on that basis, the product's ingredient profile includes compounds with published research interest.

Other options may be preferable for people who:

Need clinically validated hair loss treatment: If you have been diagnosed with androgenetic alopecia or are experiencing significant hair loss, FDA-approved treatments such as topical minoxidil or prescription finasteride have extensive published clinical trial data demonstrating efficacy in defined patient populations. A dermatologist can evaluate your specific situation and recommend evidence-based treatments tailored to your diagnosis.

Require transparent ingredient concentrations for clinical comparison: The product does not appear to publicly disclose specific per-ingredient concentrations per application. If you or your healthcare provider need this information to evaluate whether the formulation delivers research-relevant amounts of active ingredients, you may want to contact the manufacturer directly or consider products with full-disclosure labeling.

Prioritize purchasing from established retail channels: HaloGrow is sold exclusively through the official website. Consumers who prefer purchasing from retailers with established in-person return options, or who prefer the consumer protections offered by major retail platforms, may want to factor this into their decision.

Questions to ask yourself before choosing any topical hair growth product:

Have you had your hair loss evaluated by a dermatologist to determine the underlying cause? Is your hair thinning related to hormonal factors, nutritional deficiency, stress, medication, or another identifiable cause? Are you comfortable purchasing a product that uses ingredient-level research references rather than finished-product clinical trial data? Do the company's refund terms and fulfillment practices meet your expectations for consumer protection? Have you compared the product's approach to FDA-approved treatment options?

Your answers to these questions help determine which hair care characteristics matter most for your specific situation. Readers can view the current HaloGrow Hair Spray details and ingredient information on the official product page.

Is HaloGrow Hair Spray Legitimate? What "Legitimate" Means in This Category

In the topical cosmetic hair product category, consumers often use the word "legitimate" to mean several different things: whether the product is commercially available through an identifiable official website, whether ingredients are disclosed, whether refund terms are published, and whether consumers can locate clear support channels.

HaloGrow Hair Spray is marketed as a topical cosmetic product sold through the brand's official website. Consumers evaluating legitimacy commonly look at ingredient disclosures, marketing claim sourcing, refund policy requirements, and independent consumer feedback before purchasing.

Frequently Asked Consumer Questions About HaloGrow Hair Spray

Is HaloGrow a legitimate product?

HaloGrow Hair Spray is a commercially available topical hair spray sold through the official website at tryhalogrow.com. The product is also listed on public marketplace platforms under the HaloGrow brand name. It contains ingredients that appear in published peer-reviewed research at the ingredient level. The product has not been evaluated by the FDA for efficacy, which is standard for cosmetic products under current federal regulations. Consumers should evaluate the product based on the information and considerations outlined in this report, including the distinction between ingredient-level and product-level evidence.

What are the most common consumer questions about HaloGrow Hair Spray?

Consumer search patterns indicate questions about the sourcing of the "56% thicker" marketing claim, the distinction between ingredient-level and product-level research, checkout pricing accuracy, refund process reliability, the nature of the "doctor-approved" endorsement, and how the product compares to FDA-approved hair loss treatments. Each of these topics is addressed in the relevant sections above.

Does the product disclose individual ingredient concentrations?

The official website describes the formula as containing biotin, caffeine, castor oil, aminexil, ginger root extract, and He Shou Wu. Public product listings provide a fuller ingredient list. Specific concentrations per individual ingredient per application don't appear to be publicly disclosed on either the official website or product labeling reviewed for this report. Consumers may contact the manufacturer for additional details.

Is HaloGrow Hair Spray FDA approved?

This product is a topical cosmetic hair spray and doesn't require FDA approval under current federal regulations for cosmetic products. The FDA doesn't evaluate cosmetic product efficacy claims prior to market entry. The company's website includes a disclaimer stating the product is not intended to diagnose, treat, cure, or prevent any disease. This regulatory context is standard for topical hair care products in this category.

How does the refund process work?

According to the official website, the company offers a 30-day satisfaction guarantee from the date of receipt. Refund requests require contacting the company through the HaloGrow Support Portal or via the email address provided with the product packaging, and returning the product. According to the company, refunds are processed within 48 hours of the returned product being received. The buyer may be responsible for return shipping costs. Consumers should confirm current refund terms on the official website before purchasing.

Is the "56% thicker hair" claim verified by independent research?

The official website presents this figure as a marketing headline alongside an asterisk disclaimer. Publicly available materials reviewed for this report did not link this specific percentage to a published peer-reviewed clinical study evaluating the finished HaloGrow Hair Spray formula. Consumers should interpret this claim in the context of the company's published disclaimers and may request sourcing documentation from the manufacturer.

Can this product replace dermatological treatment for hair loss?

Topical cosmetic sprays are not substitutes for professional dermatological evaluation and treatment. Consumers experiencing significant hair loss should consult a healthcare provider to determine whether their hair loss has an underlying medical cause that requires clinical intervention. FDA-approved treatments for pattern hair loss include topical minoxidil and prescription finasteride, both of which have published clinical trial data supporting their use. A dermatologist can evaluate your specific situation and recommend a treatment approach based on your diagnosis.

How long does HaloGrow take to show results according to the company?

According to the official website, most users notice improved scalp health and hair texture within 4 weeks. The company states that new hair growth typically begins around 8 weeks, with more significant improvements in density and length after 12 to 16 weeks of consistent use. These are the company's stated timelines and don't represent guaranteed outcomes. Individual experiences vary based on numerous factors including the underlying cause of hair thinning, genetics, age, overall health, and consistency of application.

Is HaloGrow safe for all hair types?

According to the official website, the product is formulated with plant-based ingredients and is described as gentle and effective for all hair types. The company states it is paraben-free and suitable for use on colored or chemically treated hair. As with any topical product applied to the scalp, consumers with known sensitivities or allergies should review the full ingredient list and consider performing a patch test before full application. Consult a dermatologist if you have an existing scalp condition.

How does HaloGrow compare to other hair growth products in this category?

This evaluation focuses specifically on HaloGrow Hair Spray and doesn't provide comparative rankings. Consumers interested in comparative analysis should evaluate each product using the same verification framework: ingredient concentration transparency, published research type (ingredient-level versus product-level), manufacturing disclosure, refund terms, and independent consumer feedback patterns. Consulting a dermatologist can help you compare options based on your specific diagnosis and hair loss type.

Verification Steps Consumers Often Complete Before Purchasing

Based on the topics most frequently searched by consumers researching topical hair growth products in 2026, here are the verification steps that tend to be most useful before making a purchasing decision.

Review ingredient disclosures and look for concentration transparency. Full-disclosure labeling allows you and your healthcare provider to compare per-application amounts against published research. When specific concentrations are not listed, consider contacting the manufacturer directly to request this information. Transparency in ingredient concentrations is one of the most reliable indicators of formulation confidence.

Understand the difference between ingredient research and finished-product research. Many hair care products reference published studies on individual compounds. Fewer have been evaluated as finished multi-ingredient formulations through independent clinical trials. Knowing which type of evidence you are looking at helps set realistic expectations and allows you to make a more informed purchasing decision.

Check refund policy terms before ordering, not after. Confirm the guarantee period, required return steps, who pays return shipping, and how to initiate a refund request. Save all order confirmations, confirmation emails, and transaction records. Understanding these terms before purchasing protects you in the event that the product does not meet your expectations.

Review checkout screens carefully before completing payment. Confirm the exact quantity, per-unit price, and total charge before submitting payment. Take a screenshot of the final checkout screen for your records. This is standard consumer protection practice for any online purchase.

Research independent consumer feedback. Independent consumer feedback platforms provide perspectives beyond what appears on a company's own website. These platforms can offer a broader picture of consumer experiences, including both positive outcomes and any reported difficulties with shipping, billing, or refund processes.

Consult a qualified healthcare provider. This is especially important if you are experiencing significant hair loss, have a scalp condition, take prescription medications, or have not had your hair loss evaluated by a dermatologist. A clinician familiar with your personal medical history is the most reliable resource for evaluating whether any topical hair product is appropriate for your situation and how it compares to clinically validated treatment options.

Readers can view the current HaloGrow Hair Spray details and published terms on the official product page.

Contact Information

According to publicly available product information:

Company: HaloGrow / Halo Hair Growth

Website: tryhalogrow.com

Email: [email protected]

Support: According to the official website, customer support is accessible through the HaloGrow Support Portal. The refund request email address is provided inside the product packaging.

Guarantee: According to the official website, a 30-day satisfaction guarantee is available from date of receipt.

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, cosmetic, or dermatological advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any new hair care regimen.

Cosmetic and Health Notice: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results vary based on numerous factors including age, baseline hair and scalp condition, underlying health factors, dietary habits, genetic factors, and consistency of use. Hair loss can have multiple causes including hormonal, nutritional, medical, and genetic factors. Concerns about hair loss should be discussed with a qualified healthcare provider who is familiar with the individual's personal medical history.

Results, Pricing, and Product Variability: All pricing, promotional offers, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing (March 2026) and may change without notice. Consumers should verify current terms on the official website before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on published research and publicly available information. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes.

Visa has appointed one of its executives, Leonardo J. Collado, to lead Pismo, the provider of processing solutions for bank, FinTechs and financial institutions around the world that Visa acquired in 2024.

Collado, who is currently senior vice president at Visa and head of value-added services for Latin America and the Caribbean, will become general manager of Pismo on April 1, Visa said in a Thursday (March 5) press release.

He will succeed Vishal Dalal, who has served as general manager of Pismo since 2021 and decided to leave Visa to pursue an entrepreneurial opportunity, according to the release.

Collado has 25 years of payments industry experience and deep regional knowledge, per the release.

“We are thrilled to welcome Leo to the Pismo team — his deep payments expertise and firsthand experience scaling platform capabilities across Latin America and beyond make him the ideal leader to take Pismo into its next chapter of global growth,” Kathleen Pierce-Gilmore, senior vice president, issuer solutions at Visa, said in the release.

“At the same time, we want to recognize Vishal’s invaluable contributions to Pismo over the past several years,” Pierce-Gilmore added. “His vision and leadership have been instrumental in shaping the business, and we wish him success in his next venture.”

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Advertisement: Scroll to Continue

Collado said in a Thursday post on LinkedIn that Pismo has become a “strategic growth platform within Visa.”

“Its cloud-native platform positions Pismo to be a powerful engine for growth as the industry evolves, from agentic commerce and real-time payments to digital assets and stablecoins,” Collado said.

Visa announced in June 2023 that it planned to acquire Pismo for $1 billion cash and expand Pismo’s geographic footprint, which at the time included operation in Latin America, Asia-Pacific and Europe.

The company completed the acquisition in January 2024, saying that Visa and Pismo together would provide clients with core banking and card-issuer processing capabilities across all product types via cloud-native application programming interfaces (APIs). Visa added that the Pismo platform would also enable it to provide financial institution clients with support and connectivity for emerging payment methods and real-time payments networks.

According to the Thursday press release, Pismo has expanded from five countries to more than 20 since the acquisition. It has also signed agreements with several global banks.

Dalal said in a post on LinkedIn that he joined Pismo in 2021 and that since then, the company grew from a Brazilian FinTech to one that expanded to the regions in which it now operates.

“Now, as Pismo enters its next growth chapter, the time feels right for me to turn the page too,” Dalal said. “And after 28 years — I’m going to do something I haven’t managed to do so far — catch my breath for a bit before moving on to what comes next.”

NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=51887 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On January 29, 2026, PennyMac filed a Current Report with the Securities and Exchange Commission on Form 8-K announcing PennyMac’s fourth quarter and full-year 2025 financial results. The report stated that PennyMac’s “servicing segment pretax income was $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in the fourth quarter of 2024,” as well as “[retax income excluding valuation-related items was $47.8 million, down 70 percent from the prior quarter driven primarily by increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates drove higher prepayment activity.”

On this news, PennyMac’s stock price fell $49.78 per share, or 33.3%, to close at $99.92 per share on January 30, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com